These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 28211628)

  • 1. Editorial: relative efficacy of infliximab and adalimumab in Crohn's disease in an Australian and New Zealand cohort.
    Barreiro-de Acosta M; Gisbert JP
    Aliment Pharmacol Ther; 2017 Mar; 45(6):855-856. PubMed ID: 28211628
    [No Abstract]   [Full Text] [Related]  

  • 2. Editorial: relative efficacy of infliximab and adalimumab in Crohn's disease in an Australian and New Zealand cohort - authors' reply.
    Radford-Smith GL; Hartnell F; Doecke JD
    Aliment Pharmacol Ther; 2017 Mar; 45(6):856-857. PubMed ID: 28211631
    [No Abstract]   [Full Text] [Related]  

  • 3. Infliximab vs. adalimumab in Crohn's disease: results from 327 patients in an Australian and New Zealand observational cohort study.
    Doecke JD; Hartnell F; Bampton P; Bell S; Mahy G; Grover Z; Lewindon P; Jones LV; Sewell K; Krishnaprasad K; Prosser R; Marr D; Fischer J; R Thomas G; Tehan JV; Ding NS; Cooke SE; Moss K; Sechi A; De Cruz P; Grafton R; Connor SJ; Lawrance IC; Gearry RB; Andrews JM; Radford-Smith GL;
    Aliment Pharmacol Ther; 2017 Feb; 45(4):542-552. PubMed ID: 27995633
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tumor necrosis factor-alpha antibody for maintenance of remission in Crohn's disease.
    Behm BW; Bickston SJ
    Cochrane Database Syst Rev; 2008 Jan; (1):CD006893. PubMed ID: 18254120
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Infliximab and adalimumab-induced thrombocytopenia in a woman with colonic Crohn's disease.
    Salar A; Bessa X; Muñiz E; Monfort D; Besses C; Andreu M
    Gut; 2007 Aug; 56(8):1169-70. PubMed ID: 17344276
    [No Abstract]   [Full Text] [Related]  

  • 6. Local injection of adalimumab for perianal Crohn's disease: better than infliximab?
    Poggioli G; Laureti S; Pierangeli F; Bazzi P; Coscia M; Gentilini L; Gionchetti P; Rizzello F
    Inflamm Bowel Dis; 2010 Oct; 16(10):1631. PubMed ID: 20848458
    [No Abstract]   [Full Text] [Related]  

  • 7. Editorial: adalimumab or infliximab as monotherapy, or in combination with an immunomodulator, in the treatment of Crohn's disease.
    Christensen B; Sparrow MP
    Aliment Pharmacol Ther; 2017 Jan; 45(1):178-179. PubMed ID: 27910149
    [No Abstract]   [Full Text] [Related]  

  • 8. Adalimumab for Crohn's disease after infliximab treatment failure: a systematic review.
    Da W; Zhu J; Wang L; Lu Y
    Eur J Gastroenterol Hepatol; 2013 Aug; 25(8):885-91. PubMed ID: 23817447
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Crohn's disease outpatients treated with adalimumab have an earlier secondary loss of response and requirement for dose escalation compared to infliximab: a real life cohort study.
    Ma C; Huang V; Fedorak DK; Kroeker KI; Dieleman LA; Halloran BP; Fedorak RN
    J Crohns Colitis; 2014 Nov; 8(11):1454-63. PubMed ID: 24947334
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Editorial: first among Equals-not for either infliximab or adalimumab in Crohn's disease-yet.
    Lim MH; Doecke JD; Radford-Smith GL
    Aliment Pharmacol Ther; 2018 Apr; 47(8):1225-1226. PubMed ID: 29574876
    [No Abstract]   [Full Text] [Related]  

  • 11. Switch to adalimumab in patients with Crohn's disease controlled by maintenance infliximab: prospective randomised SWITCH trial.
    Van Assche G; Vermeire S; Ballet V; Gabriels F; Noman M; D'Haens G; Claessens C; Humblet E; Vande Casteele N; Gils A; Rutgeerts P
    Gut; 2012 Feb; 61(2):229-34. PubMed ID: 21948942
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Acute and delayed hypersensitivity reactions to infliximab and adalimumab in a patient with Crohn's disease.
    Steenholdt C; Svenson M; Bendtzen K; Thomsen OØ; Brynskov J; Ainsworth MA
    J Crohns Colitis; 2012 Feb; 6(1):108-11. PubMed ID: 22261535
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of infliximab and adalimumab in Crohn's disease: a single centre study.
    Zorzi F; Zuzzi S; Onali S; Calabrese E; Condino G; Petruzziello C; Ascolani M; Pallone F; Biancone L
    Aliment Pharmacol Ther; 2012 Jun; 35(12):1397-407. PubMed ID: 22519466
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Letter: comparative safety and efficacy of infliximab vs. adalimumab in Crohn's disease - should one consider disease location?
    Srinivas NR
    Aliment Pharmacol Ther; 2016 Oct; 44(7):771-2. PubMed ID: 27593430
    [No Abstract]   [Full Text] [Related]  

  • 15. Infliximab-induced acute hepatitis during Crohn's disease therapy: absence of cross-toxicity with adalimumab.
    Haennig A; Bonnet D; Thebault S; Alric L
    Gastroenterol Clin Biol; 2010 Sep; 34(8-9):e7-8. PubMed ID: 20189334
    [No Abstract]   [Full Text] [Related]  

  • 16. The CHOICE trial: adalimumab demonstrates safety, fistula healing, improved quality of life and increased work productivity in patients with Crohn's disease who failed prior infliximab therapy.
    Lichtiger S; Binion DG; Wolf DC; Present DH; Bensimon AG; Wu E; Yu AP; Cardoso AT; Chao J; Mulani PM; Lomax KG; Kent JD
    Aliment Pharmacol Ther; 2010 Nov; 32(10):1228-39. PubMed ID: 20955442
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Adalimumab treatment in infliximab-resistant pediatric patient with Crohn's disease].
    Veres G; Putz R; Szabó D; Molnár K; Bodánszky H; Dezsofi A; Arató A
    Orv Hetil; 2009 Oct; 150(40):1858-60. PubMed ID: 19789146
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Mechanism and therapeutic strategy of second failure of infliximab treatment for Crohn's disease].
    Kanai T; Matsuoka K; Hisamatsu T; Iwao Y; Ogata H; Hibi T
    Nihon Shokakibyo Gakkai Zasshi; 2012 Mar; 109(3):364-9. PubMed ID: 22398900
    [No Abstract]   [Full Text] [Related]  

  • 19. Adalimumab maintenance therapy for Crohn's disease with intolerance or lost response to infliximab: an open-label study.
    Peyrin-Biroulet L; Laclotte C; Bigard MA
    Aliment Pharmacol Ther; 2007 Mar; 25(6):675-80. PubMed ID: 17311600
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anti-TNF-alpha treatments and obstructive symptoms in Crohn's disease: a prospective study.
    Condino G; Calabrese E; Zorzi F; Onali S; Lolli E; De Biasio F; Ascolani M; Pallone F; Biancone L
    Dig Liver Dis; 2013 Mar; 45(3):258-62. PubMed ID: 23195667
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.